Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography

American Journal of Roentgenology

Volumn 168, Issue 2, 1997, Pages 417-424

  Flanagan, Fidelma L ^a   Dehdashti, Farrokh ^a   Siegel, Barry A ^a   Trask, Diana D ^a   Sundaresan, Sudhir R ^b   Alexander Patterson, G ^b   Cooper, Joel D ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0031016485     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.168.2.9016218     Document Type: Article

References (31)

1. Roth JA, Putnam JB Jr, Lichter AS, Forastiere AA. Cancer of the esophagus. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 4th ed. Philadelphia: Lippincott, 1993:776-817
2. Chung SCS, Stuart RC. Surgical therapy for squamous-cell carcinoma of the esophagus. Lancet 1994;343:521-523
3. Halvorsen RA Jr, Magruder-Habib K, Foster WL Jr, Roberts L Jr, Postlethwait RW, Thompson WM. Esophageal cancer staging by CT: long-term follow-up study. Radiology 1986;161:147-151
4. Anderson LL, Lad TE. Autopsy findings in squamous-cell carcinoma of the esophagus. Cancer 1982;50:1587-1590
5. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-648
6. 18F]fluorodeoxyglucose and positron emission tomography in evaluation of radiation necrosis of the brain. Radiology 1982;144:885-889
7. Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJNR 1987;8:1083-1091
8. Patronas NJ, Brooks RA, DeLaPaz RL, Smith BH, Kornblith PL, Di Chiro G. Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas. AJNR 1983;4:533-535
9. 18F] fluorodeoxy- glucose positron emission tomography. Ann Neurol 1991;29:347-355
10. Kim CK, Alavi JB, Alavi A, Reivich M. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 1991;10:85-91
11. 18F]fluorodeoxyglucose in brain tumors. In: Reivich M, Alavi A, eds. Positron emission tomography. New York: Alan Lyss, 1985:291-309
12. Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985; 62:816-822
13. Quint LE, Francis IR, Wahl RL, Gross BH, Glazer GM. Preoperative staging of non-small- cell carcinoma of the lung: imaging methods. AJR 1995;164:1349-1359
14. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evalu- ation. Radiology 1994;191:371-377
15. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265-1266
16. Wahl RL, Cody RL, Hutcnins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18)-fiuoro-2-deoxy- D-glucose. Radiology 1991;179:765-770
17. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71:3920-3925
18. Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992;216:27-34
19. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18]2-deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743-750
20. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer, comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;6:1766-1774
21. Xu M, Luk WK, Cutler PD, Digby WM. Local threshold for segmented attenuation correction of PET imaging of the thorax. IEEE Trans Nucl Sci 1994;41:1532-1537
22. Inculet RI, Keller SM, Dwyer A, Roth JA. Evaluation of noninvasive tests for the preoperative staging of carcinoma of the esophagus: a prospective study. Ann Thorac Surg 1985;40:561-565
23. Urmacher C, Brennan MF. Preoperative staging of esophageal cancer: comparison of endoscopic US and dynamic CT. Radiology 1991;181:419-425
24. Duignan JP, McEntee GP, O'Connell DJ, Bouchier-Hayes DJ, O'Malley E. The role of CT in the management of carcinoma of the oesophagus and cardia. Ann R Coll Surg Engl 1987;69:286-288
25. Becker CD, Barbier P, Porcellini B. CT evaluation of patients undergoing transhiatal esophagectomy for cancer. J Comput Assist Tomogr 1986;10:607-611
26. Halvorsen RA Jr, Thompson WM. Primary neo- plasms of the hollow organs of the gastrointestinal tract. Cancer 1991;67:1181-1188
27. 18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 1990;31:1831-1835
28. Fukunaga T, Enomoto K, Okazumi S, et al. Analysis of glucose metabolism in patients with esophageal cancer by PET: estimation of hexokinase activity in the tumor and usefulness for clinical assessment using FDG. Nippon Geka Gakkai Zasshi 1994;95:317-325
29. Abdel-Nabi H, Spauiding MB, Doerr RJ, Lamonica D, Steinbrenner L, Gona J. Pre-operative staging of gastroesophageal cancers with F-18 fluorodeoxy- glucose (FDG) positron emission tomography (abstr). J Nucl Med 1996; 37 [suppl]: 135P
30. Picus D, Balfe D, Koehler RE, Roper C, Owel JW. CT in the staging of esophageal carcinoma. Radiology 1983;146:433-438
31. Tio TL, Coene PP, Luiken GJ, et al. Endosonography in the clinical staging of esophagogastric carcinoma. Gastrointesl Endosc 1990;36:S2-S10